Cole Garry T, Hurtgen Brady J, Hung Chiung-Yu
Department of Biology and South Texas Center for Emerging Infectious Diseases (STCEID), University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA.
Curr Fungal Infect Rep. 2012 Dec 1;6(4):235-244. doi: 10.1007/s12281-012-0105-y.
Coccidioidomycosis (San Joaquin Valley fever) is a human respiratory disease caused by a soil-borne mold, and is recognized as an intransigent microbial infection by physicians who treat patients with the potentially life-threatening, disseminated form of this mycosis. Epidemiological studies based on surveys of skin-test reactivity of people who reside in the endemic regions of the Southwestern US have shown that at least 150,000 new infections occur annually. The clinical spectrum of coccidioidomycosis ranges from an asymptomatic insult to a severe pulmonary disease in which the pathogen may spread from the lungs to the skin, bones, brain and other body organs. Escalation of symptomatic infections and increased cost of long-term antifungal treatment warrant a concerted effort to develop a vaccine against coccidioidomycosis. This review examines recently reported strategies used to generate such a vaccine and summarizes current understanding of the nature of protective immunity to this formidable disease.
球孢子菌病(圣华金谷热)是一种由土壤传播的霉菌引起的人类呼吸道疾病,对于治疗这种可能危及生命的播散型真菌病患者的医生来说,它被认为是一种顽固的微生物感染。基于对居住在美国西南部流行地区人群皮肤试验反应性调查的流行病学研究表明,每年至少发生15万例新感染。球孢子菌病的临床谱范围从无症状感染到严重的肺部疾病,在严重肺部疾病中病原体可能从肺部扩散到皮肤、骨骼、大脑和其他身体器官。有症状感染的增加以及长期抗真菌治疗成本的上升,使得人们有必要齐心协力研发一种针对球孢子菌病的疫苗。这篇综述研究了最近报道的用于研发这种疫苗的策略,并总结了目前对这种严重疾病保护性免疫本质的理解。